UBS Maintains Neutral on IDEXX Laboratories, Lowers Price Target to $640
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst Andrea Alfonso maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and lowers the price target from $730 to $640.
UBS analyst Andrea Alfonso maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and lowers the price target from $730 to $640.